LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.
Access to Care & Reimbursement
Support for policies to improve access to care
Cancer Leadership Council Comments on CMS Notice of Payment and Benefit Parameters for 2025 (January 8, 2024)
All Copays Count Coalition Comments on CMS Notice of Benefit and Payment Parameters for 2025 (January 8, 2024)
MAPRx Comments on CY2025 Medicare Advantage and Part D Proposed Rule Comment Letter (January 5, 2024)
LUNGevity Comments on CLFS CY2024 Preliminary Determinations (October 27, 2023)
All Copays Count Coalition Letter on NBPP Court Decisions and Copay Accumulators (October 6, 2023)
Group Letter to CMS on Comparative Effectiveness Considerations for Selected Oncology Drugs (October 2, 2023)
Cancer Leadership Council Letter on Physician Fee Scheduled CY 2024 Proposed Rule (September 11, 2023)
Stakeholder Letter on Transitional Coverage for Emerging Technologies (TCET) Proposed Pathway (August 28, 2023)
All Copays Count Coalition Letter Supporting Inclusion of HELP Copays Act in PBM Reform Package (July 14, 2023)
LUNGevity Statement in Support of the Comprehensive Cancer Survivorship Act (June 28, 2023)
LUNGevity Statement in Support of the Increasing Access to Lung Cancer Screening Act (June 26, 2023)
2023 Stakeholder Letter in Support of the SALSA Act (June 7, 2023)
Community Letter to CMS on Medicare Part D Redesign Implementation (June 5, 2023)
Health Groups Applaud Stay on Braidwood v Becerra Lawsuit to Protect Coverage for Preventive Services (May 15, 2023)
All Copays Count Coalition Letter of Support for HELP Copays Act - Senate (May 10, 2023)
Cancer Leadership Council Comments on CMS Initial Memorandum for Implementation of the Medicare Drug Price Negotiation Program (April 14, 2023)
MAPRx Comments on CMS Initial Memorandum for Implementation of the Medicare Drug Price Negotiation Program (April 14, 2023)
Rare Disease Patient Organization Sign-on Letter to CMS on Initial Memorandum for Implementation of the Medicare Drug Price Negotiation Program (April 14, 2023)
Partnership to Fight Chronic Disease Sign-on Letter to CMS on Initial Memorandum for Implementation of the Medicare Drug Price Negotiation Program (April 14, 2023)
MAPRx Comments on Medicare Program Contract Year 2024 Proposed Rule (February 13, 2023)
Cancer Leadership Council Comments on Medicare Program Contract Year 2024 Proposed Rule (February 13, 2023)
Cancer Leadership Council Comments on CMS Request for Information on Essential Health Benefits (January 31, 2023)
Cancer Leadership Council Comments on CMS Notice of Benefit and Payment Parameters for 2024 (January 30, 2023)
Cancer Leadership Council Recommendations to Congress for 2022 Year-End Funding and Legislative Package (November 22, 2022)
Stakeholder Sign-on Letter to Senate Urging Action on Extended Telehealth Access (September 13, 2022)
Stakeholder Sign-on Letter to Congressional Leaders in Support of the Saving Access to Laboratory Services Act (September 13, 2022)
Partner Sign-on Letter to Gov. Newsom in Support of SB 912 and Coverage for Biomarker Testing (September 1, 2022)
Cancer Leadership Council Comments to CMS on Medicare Advantage (August 31, 2022)
LUNGevity Letter on Healthcare Provisions in the Inflation Reduction Act of 2022 (August 5, 2022)
Cancer Leadership Council Sign-on Letter on the Inflation Reduction Act of 2022 (August 5, 2022)
LUNGevity Comments for the Novitas Proposed Local Coverage Determination, “Genetic Testing for Oncology (DL39365)” (July 23, 2022)
LUNGevity Comments for the First Coast Proposed Local Coverage Determination, “Genetic Testing for Oncology (DL39367)” (July 23, 2022)
Stakeholder letter to HHS to Support Telehealth Resource Centers (May 31, 2022)
Stakeholder Sign-on Letter to Congressional Leaders in Support of the Equitable Community Access to Pharmacist Services Act (March 25, 2022)
Centers for Medicare and Medicaid Services’ Proposed Decision Memo: Monoclonal Antibodies Directed against Amyloid for the Treatment of Alzheimer’s Disease (February 9, 2022)
LUNGevity Comments for the Proposed Local Coverage Determination, “Genomic Sequence Analysis
Panels in the Treatment of Solid Organ Neoplasms (DL37810)” (December 30, 2021)
Medicare Proposed National Coverage Decision (CAG‐00439R): Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (December 17, 2021)
LUNGevity Comments re: National Determination on Screening for Lung Cancer 2021 (June 17, 2021)
Sign-on letter to HHS re: CMMI Part D Payment Modernization Models/ 6 Protected Classes (February 4, 2021)
NHC and NMQF Health Equity Consensus Statement (December 2020)
CLC Letter to HHS re: Most Favored Nation Model (December 22, 2020)
Cancer Leadership Council Letter on Most Favored Nation Interim Final Rule (December 22, 2020)
LUNGevity Statement in Response to Most Favored Nation Policy (December 16, 2020)
LUNGevity Foundation Sign-on Letter to CMS on the Laboratory Date of Service/14-Day Rule Policy (October 5, 2020)
All Copays Count Coalition Letter to House Leadership re: Delaying the 2021 NBPP (September 29, 2020)
CLC Comments on Medicare PFS CY 2022 (September 13, 2021)
Sign-on letter to House Veterans Affairs Committee on multiple issues (September 8, 2020)
LUNGevity comments to USPSTF on draft lung cancer screening guidelines (August 3, 2020)
LUNGevity comment to Cigna re: Impact of 2020 National Preferred Formulary Exclusions on Lung Cancer Patients (June 23, 2020)
Sign-on letter to Express Scripts re: 2020 National Preferred Formulary Exclusions Impact on Cancer Patients (June 30, 2020)
Cancer Leadership Council on Fifth Circuit Opinion, Texas v US (December 20, 2019)
Cancer Leadership Council on Oncology Care First (December 13, 2019)
LUNGevity Foundation Comments to CMS on Proposed Decision Memo for Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer (November 27, 2019)
LUNGevity comments on Premera BCBS Guidelines for Molecular Testing (October 31, 2019)
LUNGevity comments on the ICER 2020 Value Assessment Framework (October 18, 2019)
Public health groups support prohibition of menthol cigarettes (October 16, 2019)
Coalition comments on Graphic Warnings Proposed Rule (October 15, 2019)
LUNGevity Foundation Sign-on Letter to CMS on the Laboratory Date of Service/14-Day Rule Policy (September 27, 2019)
LUNGevity Foundation Comment Letter to CMS on the Laboratory Date of Service/ 14-Day Rule Policy (September 13, 2019)
MAPRx Coalition Letter to Senate Finance Committee (July 25, 2019)
LUNGevity comments on the ICER 2020 Value Assessment Framework (June 10, 2019)
MapRx comment letter on out-of-pocket cap to Ways and Means and Energy and Commerce Committees (June 6, 2019)
CLC sign-on letter on out-of-pocket cap to Ways and Means and Energy and Commerce Committees (June 6, 2019)
Community Letter in Support of The Women and Lung Cancer Act of 2019 (May 1, 2019)
MapRx Comment Letter on Proposed Removal of Safe Harbor for Rebates (April 8, 2019)
Coalition Letter in Support of State Medicaid Coverage for Lung Cancer Screening (March 19, 2019)
Cancer Leadership Council Letter to Senator Alexander re: Health Care Costs (March 1, 2019)
Cancer Leadership Council Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)
CSC Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)
Partnership for Part D Access Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)
Cancer Leadership Council letter to HHS on the International Pricing Index (IPI) model for Medicare Part B drugs (December 31, 2018)
CSC comment letter to HHS on the International Pricing Index (IPI) model for Medicare Part B drugs (December 31, 2018)
Cancer Leadership Council Statement on Affordable Care Act Ruling (December 18, 2018)
Cancer Leadership Council comments on drug pricing transparency proposal (December 17, 2018)
LUNGevity Comments on Inivata Liquid LCD (November 15, 2018)
Letter to House & Senate – Part B MA Step Therapy (September 26, 2018)
ASP Medicare Part B Step Therapy Letter (September 12, 2018)
Patient Group Letter to CVS (September 12, 2018)
Patient & Provider Comments to CMS on DME Oxygen (September 6, 2018)
LUNGevity NGS Comments to Oregon HERC (August 13, 2018)
PAN Patient Community HHS Blueprint Letter (July 16, 2018)
REAP Coalition HHS Blueprint Letter (July 16, 2018)
CSC HHS Blueprint Letter (July 15, 2018)
LUNGevity Comments on Guardant360 LCD – May 2018 (May 9, 2018)
Cancer Care Planning and Communication Act, H.R. 5160 (March 14, 2018)
Right to Try Coalition Letter (House) (March 12, 2018)
Right to Try (S.204 & H.R. 878) (February 6, 2018)
LUNGevity NGS National Coverage Determination Comments to CMS (January 17, 2018)
LUNGevity CMMI 2017 RFI Comments (November 20, 2017)
REAP Coalition CMMI 2017 RFI (November 20, 2017)
Veterans Affairs ICER Letter (November 13, 2017)
MassHealth 1115 Waiver Letter 2017 (October 18, 2017)
340B Drug Discount Program (September 27, 2017)
Sign-On HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 11, 2017)
LUNGevity HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 7, 2017)
Guardant360 LCD 2017 (July 19, 2017)
Medicaid Expansion and Per Capita Caps (June 15, 2017)
Letter on Patient Protection and Affordable Care Act; Market Stabilization (March 7, 2017)
Regence reimbursement policy letter (February 14, 2017)
Letter to House (February 6, 2017)
Letter to Senate (February 6, 2017)
Joint letter to Congress (February 2, 2017)
Letter on ICER draft document for NSCLC (September 15, 2016)
Partnership to Improve Patient Care ICER letter (September 12, 2016)
Letter to CMS supporting screening (October 8, 2014)
Clinical Trials
Multi-Stakeholder Concerns regarding IVDR and Patient Access to Clinical Trials (March 17, 2023)
Community Sign-on Letter to the Senate re: PDUFA and Diversity in Clinical Trials (June 8, 2022)
Community Letter in Support of Clinical Trial Diversity (May 11, 2022)
Sign-on letter in support of the Clinical Treatment Act (HR 913/ S 4742) (October 9, 2020)
Coalition sign-on response to ClinicalTrials.gov RFI (March 13, 2020)
COVID-19
Sign-on Letter to the White House on the Importance of Additional COVID-19 Vaccine and Treatment Options (November 17, 2022)
Sign-on Letter to FDA on the Importance of Additional COVID-19 Vaccine and Treatment Options (July 20, 2022)
Sign-on letter to National Academies of Medicine re: COVID-19 Vaccine Allocation (September 4, 2020)
All Cancers Congress sign-on letter in response to Cancer Discrimination in Star County, Texas (August 17, 2020)
Sign-on Cancer Community Letter to Congress on patient priorities for COVID negotiation package (July 28, 2020)
Sign-on Letter to Vice President Pence in Support of Science-Based Health Policy (July 15, 2020)
Sign-on letter to NCI on Telehealth Research Gaps (July 30, 2020)
Sign-on letter to Chairman Alexander regarding pandemic preparedness (June 26, 2020)
Sign-on letter to Office of Civil Rights on emergency triage plans (May 20, 2020)
Cancer community anti-discrimination sign-on letter to governors (April 21, 2020)
Cancer community sign-on letter to Hill leadership regarding important policy changes for cancer patients during COVID crisis (April 15, 2020)
Cancer community sign-on letter to HHS regarding important policy changes for cancer patients during COVID crisis (April 15, 2020)
Joint Statement on COVID-19 Triage of Lung Cancer Patients (April 7, 2020)
HHS's Guidance on Avoiding Disability-Based Discrimination in Treatment Rationing (April 3, 2020)
Letter to Congress: Medications Access Must be Included in Third COVID-19 package (March 26, 2020)
Letter to President Trump: Domestic manufacture of health care products (March 25, 2020)
Letter to Congress: Potential Aid for Patient Organizations Impacted by Coronavirus (March 26, 2020)
The Charitable Sector: COVID-19 Relief and Economic Stimulus Package (March 23, 2020)
Letter to states to protect access to medications for high-risk populations during COVID-19 (March 20, 2020)
Diagnostics Testing Regulation
Urging policymakers to include FDA involvement in the regulation of lab-developed tests
LUNGevity Comments on Proposed Rule on the Regulation of Laboratory-Developed Tests (December 1, 2023)
LUNGevity Comments on VALID Act of 2022 (May 22, 2022)
Diagnostic Reform Coalition Letter (August 8, 2018)
Diagnostic Reform Coalition Letter – May 2018 (May 9, 2018)
Letter to the House on Regulation of Lab-Developed Tests (January 24, 2017)
Letter to the Senate on Regulation of Lab-Developed Tests (January 24, 2017)
Letter to House on Regulation of Lab-Developed Tests (April 1, 2016)
Letter to Senate on Regulation of Lab-Developed Tests (April 1, 2016)
Federal Research Funding
Requesting funding increases for cancer research
DHRC Letter to Congressional Leadership - Defense Appropriations and CDMRP (October 27, 2023)
Lung Cancer Partners Letter on FY2024 Funding (July 26, 2023)
Partners Letter on FY2024 Public Health Funding (July 19, 2023)
FY2024 Defense Health Research Appropriations Letter - House (April 24, 2023)
FY2024 Defense Health Research Appropriations Letter - Senate (April 24, 2023)
FOVA FY2024 Appropriations Recommendation (March 27, 2023)
OVAC FY2024 Appropriations Request Letter (March 20, 2023)
Ad Hoc Group for Medical Research FY2024 Recommendation for NIH (March 14, 2023)
Defense Health Research Consortium Letter Supporting FY2023 Funding for Congressionally Directed Medical Research Programs (November 21, 2022)
Ad Hoc Group for Medical Research FY2023 Recommendation for NIH (2022)
FOVA FY2023 Appropriations Recommendation (April 26, 2022)
DHRC Letter in Support of the 2022 Defense Appropriations Act and CDMRP Funding (October 2021)
Friends of VA Medical Care and Health Research 2022 Recommendations for VA Research (February 2021)
Scientific and Research Community Sign-on letter re: FY2021 Appropriations (December 8, 2020)
One Voice Against Cancer (OVAC) FY19 Conferee Letter (September 12, 2018)
FY2019 EPA Appropriations – Senate & House (May 11, 2018)
FY2019 Defense Appropriations – House (May 8, 2018)
FY2019 Defense Appropriations – Senate (May 8, 2018)
OVAC FY2019 Appropriations Request Letter to House (March 12, 2018)
OVAC FY2019 Appropriations Request Letter to Senate (March 12, 2018)
FY2019 NDAA Letter for Defense Health Research Programs (February 27, 2018)
OVAC FY2018 Budget Letter to House (February 21, 2018)
OVAC FY2018 Budget Letter to Senate (February 21, 2018)
NDAA Congressionally Directed Medical Research Programs Letter (October 25, 2017)
OVAC FY2018 Budget Deal Letter (November 1, 2017)
Congressionally Directed Medical Research Programs (September 8, 2017)
OVAC FY 2018 Appropriations Request
Food and Drug Administration (FDA)
Support for FDA appointment nominees and initiatives to streamline the cancer drug approval process
LUNGevity Comments on Decentralized Clinical Trials Draft Guidance (July 31, 2023)
LUNGevity Comments on Fourth PFDD Draft Guidance (July 1, 2023)
LUNGevity Comments on Accelerated Approval of Oncology Therapeutics Draft Guidance (May 25, 2023)
LUNGevity Comments on Externally Controlled Trials Draft Guidance (May 2, 2023)
LUNGevity Comments on Dose Optimization Guidance (March 20, 2023)
LUNGevity Comments on Patient-Focused Drug Development: Selecting, Developing, or Modifying Fitfor-Purpose Clinical Outcome Assessments (October 12, 2022)
Inclusion of reforms to the accelerated approval pathway in end-of-the-year PDUFA (prescription drug user fee act) legislation (September 20, 2022)
A4 Letter to Congress AA in PDUFA (August 1, 2022)
Accelerated Approval Action Alliance (A4) Sign-on Letter re: Accelerated Approval Consensus Themes (June 16, 2022)
LUNGevity Comments re: Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products (February 28, 2022)
LUNGevity Comments re: Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products (January 24, 2022)
LUNGevity PDUFA VII comments (August 23, 2020)
Sign-on Letter of Support for Dr. Sharpless as FDA Commissioner (September 3, 2019)
LUNGevity Comments on FDA Draft Guidance to Enhance Diversity of Clinical Trial Populations (August 6, 2019)
Coalition Letter in Response to FDA Guidance Documents Concerning Cancer Clinical Trial Eligibility Criteria (May 13, 2019)
FDA Government Shutdown Community Sign-on Letter (January 22, 2019)
MODERN Labeling Act (November 15, 2018)
LUNGevity Comments to FDA on Patient-Focused Drug Development Guidance (September 11, 2018)
LUNGevity Comments on FDA Technical Assistance for Diagnostics Accuracy and Innovation Act (August 20, 2018)
Oncology Center of Excellence (OCE) (August 3, 2017)
Enhancing Patient Engagement Efforts Across FDA (June 12, 2017)
Coalition for Clinical Trials Awareness letter (April 7, 2017)
Gottlieb support letter (April 4, 2017)
Gottlieb support letter (March 13, 2017)
Friends of the Cancer Policy Institute letter (January 31, 2017)
Oncology Center for Excellence letter (June 6, 2016)
Califf support letter (February 19, 2016)
Public Health
Cancer Community Letter to Administration on Menthol and Flavored Cigar Rules (December 13, 2023)
Cancer Leadership Council Letter of Support - Dr. Bertagnolli for NIH Director (October 16, 2023)
Public Health Partners Response to House Budget RFI (October 15, 2023)
Community Letter of Support to Senate Leaders - Dr. Bertagnolli for NIH Director (October 13, 2023)
Partners Coalition Letter in Support of the Helping Tobacco Users Quit Act (September 28, 2023)
OVAC Letter of Support - Dr. Bertagnolli NIH Director Nomination (June 20, 2023)
Community Letter of Support - Dr. Bertagnolli NIH Director Nomination (June 12, 2023)
Health Partners Letter Opposing the REINS Act (March 17, 2023)
2023 Sign-on Letter in Support of the PASTEUR Act to Combat Antimicrobial Resistance (March 8, 2023)
Coalition Letter Supporting FDA Proposed Rule on Menthol Cigarettes and Flavored Cigars (February 21, 2023)
2022 Sign-on Letter in Support of the PASTEUR Act to Combat Antimicrobial Resistance (November 16, 2022)
Joint Statement: Remove Flavored E-Cigarettes from the Market (November 18, 2019)
21st Century Cures / Cures 2.0
Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation
LUNGevity Comments on Cures 2.0 (November 12, 2021)
Cancer Leadership Council feedback on Cures 2.0 (December 16, 2019)
Letter to House and Senate (November 16, 2016)